BFH772 (VEGFR2 inhibitor): Technical Guidance for Research Applications

What This Product Solves

BFH772 is a small molecule VEGFR2 inhibitor with high selectivity and potency, developed for research into VEGFR2-mediated angiogenesis. Its primary application is in studies where precise inhibition of the VEGFR2 signaling pathway is required—most notably in tumor angiogenesis models. The compound's selectivity profile minimizes off-target effects on related kinases, making it well suited for dissecting VEGFR2-specific biological functions. Due to its solubility and selectivity characteristics, BFH772 is not appropriate for workflows that require water-soluble inhibitors or those aiming to broadly suppress multiple kinase pathways. For detailed product data and certificates, refer to the BFH772 (VEGFR2 inhibitor) page at APExBIO.

Protocol Parameters

• Assay: VEGFR2 kinase inhibition | Value: IC₅₀ = 3 nM | Applicability: Suitable for assays targeting VEGFR2 signaling pathways | Rationale: Enables potent inhibition of VEGFR2-mediated angiogenesis without extensive off-target activity | Source type: Product dossier
• Assay: Compound solubility | Value: ≥53.4 mg/mL in DMSO, ≥15.33 mg/mL in ethanol, insoluble in water | Applicability: Appropriate for DMSO- or ethanol-based in vitro and in vivo workflows; not suitable for aqueous systems | Rationale: Ensures compound can be accurately dosed in compatible solvents; avoid water-based protocols | Source type: Product dossier
• Assay: Storage conditions | Value: -20°C, avoid long-term solution storage | Applicability: Maintain compound integrity during storage and experiment setup | Rationale: Prevents degradation or potency loss due to suboptimal storage conditions | Source type: Product dossier
• Assay: Selectivity against related kinases (FLK-1, FLT-1, FLT-4, B-RAF, RET, TIE-2) | Value: ≥40-fold lower efficacy than VEGFR2 | Applicability: For workflows requiring minimal off-target kinase inhibition | Rationale: Reduces confounding effects in pathway-specific studies | Source type: Product dossier

Workflow Setup and QC Checklist

To ensure reproducibility and data integrity when using BFH772 as a VEGFR2 kinase inhibitor for angiogenesis research, follow these workflow best practices:

• Solvent Preparation: Dissolve BFH772 in DMSO or ethanol at the required concentration for your assay. Due to its insolubility in water, pre-test dilution protocols to confirm complete dissolution before use. For detailed protocol considerations, see the Technical Protocols and Use Guide.
• Aliquoting and Storage: Prepare small aliquots to minimize freeze-thaw cycles. Store powder at -20°C. Avoid storing solutions for extended periods, as stability data supports only short-term solution use.
• Quality Control: Confirm each batch’s purity (should be >96%) using the provided certificate of analysis. Cross-check batch QC with the accompanying safety data sheet and, if available, perform in-house verification of identity and purity.
• Assay Controls: Always include appropriate vehicle controls (DMSO or ethanol) to account for solvent effects in both cell-based and animal models.
• Dosing Accuracy: Use precision pipettes and freshly prepared solutions to ensure consistency in dosing, given the compound’s high potency at nanomolar concentrations.
• Record-Keeping: Document batch numbers, preparation date, solvent lot, and storage conditions for traceability and reproducibility.
• Reference Internal Guidance: The article Technical Guidance & Protocols provides additional details on workflow design and assay compatibility specific to BFH772.

Common Failure Modes and Fixes

• Poor Dissolution: If BFH772 does not dissolve fully in DMSO or ethanol, ensure the solvent is at room temperature and vortex thoroughly. Sonication may help if necessary. Do not attempt to dissolve in water, as the compound is insoluble.
• Compound Precipitation in Aqueous Media: If precipitation occurs after dilution into aqueous buffers or cell culture media, further reduce the DMSO/ethanol concentration or add immediately prior to use. Maintain solvent concentrations within cell-tolerant limits (typically ≤0.1–0.5% v/v in final assays, as a workflow recommendation).
• Loss of Activity: Degradation or potency loss may result from prolonged solution storage or repeated freeze-thaw cycles. Always use freshly prepared aliquots and avoid storing solutions beyond one week, even at -20°C.
• Off-target Effects: If unexpected biological activity is observed, review experimental design to ensure that VEGFR2 is the primary target pathway. Confirm that no protocol steps introduce additional kinase inhibitors or confounders.
• Batch-to-Batch Variability: Always compare new lots against past QC reports and, if possible, perform a reference inhibition assay to confirm consistency.

Scope and Limitations

BFH772 is validated for use as a VEGFR2 signaling pathway inhibitor in research settings focused on angiogenesis and tumor growth. Its high selectivity (≥40-fold lower efficacy against non-VEGFR2 kinases) makes it unsuitable for studies requiring broad-spectrum kinase inhibition. The compound’s insolubility in water further restricts its use to DMSO or ethanol-based protocols; workflows that require fully aqueous reagents or high-throughput aqueous screening are not compatible. Researchers should be aware that BFH772 is not intended for diagnostic or therapeutic use in humans, and its performance outside the context of VEGFR2-driven angiogenesis must be independently validated. Refer to BFH772 (VEGFR2 inhibitor) for the most recent technical documentation.

Conclusion

BFH772 is a potent, highly selective angiogenesis inhibitor tailored for VEGFR2 pathway research, particularly in tumor model systems. Its precise selectivity and robust QC documentation from APExBIO facilitate reproducible, targeted experimental designs, provided workflows are adapted to its solubility and storage requirements. For further technical protocols and troubleshooting, consult the referenced internal articles specific to BFH772, ensuring optimal integration into your angiogenesis research applications.